Long-term outcomes of de novo acute myeloid leukemia in Thai patients

Journal of the Medical Association of Thailand

Volumn 92, Issue 9, 2009, Pages 1143-1149

  Niparuck, Pimjai ^a   Chuncharunee, Suporn ^a   Ungkanont, Artit ^a   Udomtrupayakul, Umaporn ^a   Aungchaisuksiri, Puntep ^a   Rerkamnuatchoke, Budsaba ^a   Jootar, Saengsuree ^a   Atichartakarn, Vichai ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Acute myeloid leukemia; Prognosis; Treatment outcome

Indexed keywords

CYTARABINE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; METHOTREXATE; MITOXANTRONE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC RISK; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; THAILAND; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; THAILAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349295242     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Saxena A, Sheridan DP, Card RT, McPeek AM, Mewdell CC, Skinnider LF. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol 1998; 58: 278-284 (Pubitemid 28346013)
2. Ogata K, Yokose N, Shioi Y, Ishida Y, Tomiyama J, Hamaguchi H, et al. Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br J Haematol 2001; 115: 612-615 (Pubitemid 34015652)
3. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox-Froncillo MC, Aronica G, et al. Prognostic cases of acute myeloid leukemia. Leukemia 1998; 12: 1056-1063
4. Slobinas A, Matuzevi□ien□ R. The immunophenotype of adults with acute myeloid leukemia: proposal of prognostic value. Acta Medica Lituanica 2005; 12: 54-59
5. Cripe LD, Hinton S. Acute myeloid leukemia in adults. Curr Treat Options Oncol 2000; 1: 9-17.
6. Curtis JE, Messner HA, Minden MD, Minkin S, McCulloch EA. High-dose cytosine arabinoside in the treatment of acute myelogenous leukemia: contributions to outcome of clinical and laboratory attributes. J Clin Oncol 1987; 5: 532-543 (Pubitemid 17062489)
7. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981; 58: 1203-1212 (Pubitemid 12251149)
8. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997; 90: 2978-2986 (Pubitemid 27444191)
9. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217-223
10. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996; 10: 1874-1882 (Pubitemid 27019632)
11. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-1656 (Pubitemid 28550689)
12. Brincker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep 1985; 69: 5-11. (Pubitemid 15197068)
13. Griffiths EA. Acute myeloid leukemia: Risk stratification and therapy selection in the era of molecular diagnostics. The Molecular Oncology Report 2007; 1: [11 screens].
14. Enjeti AK, Tien SL, Sivaswaren CR. Cytogenetic abnormalities in de novo acute myeloid leukemia in adults: relation to morphology, age, sex and ethnicity - a single center study from Singapore. Hematol J 2004; 5: 419-425
15. Nakase K, Bradstock K, Sartor M, Gottlieb D, Byth K, Kita K, et al. Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases. Leukemia 2000; 14: 163-168 (Pubitemid 30068388)
16. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302
17. The value of c-kit in the diagnosis of biphenotypic acute leukemia. EGIL (European Group for the Immunological Classification of Leukaemias). Leukemia 1998; 12: 2038. (Pubitemid 28554480)
18. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336 (Pubitemid 35429670)
19. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083
20. Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 5705-5717